NASH

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress

Retrieved on: 
Tuesday, January 9, 2024
Biology, Fibrosis, Organovo, UC, SAN, Partnership, Tissue, IBD, Inflammatory bowel disease, Executive, Cirrhosis, Research and development, Disease, 3D, NASH, Colitis, Ulcerative colitis, FXR, Ulcer

The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.

Key Points: 
  • The invited oral presentation, entitled “Evaluation of the clinical stage FXR agonist FXR314 in human primary cell 3D models of Crohn’s disease and ulcerative colitis”, will be made on Friday, January 26, 2024 at 3:00 PM PST by Dr. Fabrice Piu, Vice President, Research & Development.
  • “We initially identified a strong benefit of FXR agonism in IBD using our internal 3D models, then moved towards development of what we believe to be a best-in-class FXR agonist, FXR314, to treat IBD,” said Keith Murphy, Organovo's Executive Chairman.
  • Organovo plans to begin enrollment for a proof-of-concept Phase 2 ulcerative colitis study in 1H 2024, with targeted completion in 1H 2025.
  • The drug’s additional promise in liver fibrosis and NASH makes it a strong candidate for development in that area through partnership collaborations with Organovo.

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Continuity, Diabetes, Entrepreneurship, Risk, C3, Non-alcoholic fatty liver disease, Epilepsy, FDA, CR2, Anticonvulsant, Inflammation, Neuron, Geographic atrophy, Conference, Paratriathlon, Pain, European, Disease, Cmax, Glycated hemoglobin, Trigeminal neuralgia, FGF21, Steatosis, Therapy, Computational biology, Exophthalmos, TED, Diplopia, Varenicline, Smoking, Injection, AAV, CNS, DSM-IV codes, Patient, Graves' ophthalmopathy, Medicine, Seizure, Glucokinase, Neurology, CR1, NASH, Insulin, Brain, GMP, Trigeminal nerve, Ophthalmology, Pathology, Fibrosis, Pharmaceutical industry

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy. Kriya is advancing the first of its gene therapy product candidates into the clinic in 2024 and expects up to five programs in the clinic by the end of 2025.

Key Points: 
  • Kriya’s pipeline includes gene therapies across three major therapeutic areas: ophthalmology, metabolic disease and neurology.
  • Its programs share the following features: direct-to-tissue delivery, validated biology, de-risked clinical and regulatory paths and large commercial markets.
  • Dr. Ramaswamy will share further information on Kriya’s portfolio during his presentation at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th at 9:00 AM PT in San Francisco, California.
  • A significant proportion of patients suffer from refractory epilepsy, many of whom are candidates for invasive neurosurgery.

Boston Pharmaceuticals Presents Data at NASH-TAG 2024 Demonstrating Low Immunogenicity Over Time With Long-acting FGF21 Analogue, BOS-580, for MASH

Retrieved on: 
Friday, January 5, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, NAFLD, Risk, ADAS, NASH, Division, Hepatology, Non-alcoholic fatty liver disease, ADAPT, CMO, Prevalence, University of California, Medication, Liver injury, University, Fatty liver disease, MASH, Biomarker, FAST, FGF21, Patient, Fibrosis, Therapy, Aspartic acid

The data were presented at NASH-TAG 2024 (Jan. 4-6, 2024) in Park City, Utah.

Key Points: 
  • The data were presented at NASH-TAG 2024 (Jan. 4-6, 2024) in Park City, Utah.
  • “This low immunogenicity distinguishes BOS-580 from other FGF21 analogues currently in development.”
    Another analysis of data from Boston Pharmaceuticals’ Phase 2a trial demonstrated the impact of BOS-580 treatment on several non-invasive indicators of fibrosis based on markers of liver injury and fibrosis in MASH patients.
  • “Our latest data highlight that BOS-580 has great potential to become a backbone in the treatment of patients suffering from MASH.
  • We believe BOS-580 may offer a compelling and convenient treatment option for people living with MASH,” said Juan Carlos Lopez-Talavera, M.D., Ph.D., CMO of Boston Pharmaceuticals.

Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, January 4, 2024
CML, Conference, NASH, GIPR, Publishing, Head, DSM-IV codes, Obesity, THR, Webcast, Pharmaceutical industry

FOSTER CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that management will provide an update on its pipeline and strategic priorities for 2024 during the Company’s presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 10th, 2024 at 1:30pm PT.

Key Points: 
  • “2023 was a highly productive year for Terns as we made significant strides towards achieving our mission to bring better, novel medicines to people living with diseases of significant unmet medical need.
  • “As we move into 2024, we are prioritizing capital allocation towards our oncology and obesity programs, while limiting near-term development spend on TERN-501 in NASH.
  • Based on the potential best-in-class efficacy and safety profile shown in the Phase 2a DUET trial, we remain encouraged by the potential of TERN-501 beyond NASH, particularly in obesity, where we believe it could have a meaningful treatment benefit in combination with other therapies.
  • A replay of the webcast will be archived on Terns’ website for 30 days following the presentation.

Target RWE Launches Novel Precision Medicine Platform to Undertake Growing Unmet Medical Needs in Liver Disease, Gastroenterology, and Immune-mediated Inflammatory Conditions

Retrieved on: 
Thursday, January 4, 2024
Doctor of Pharmacy, Dermatology, Medicine, RWE, NASH, Drug development, Research, Plasma, Doctor of Philosophy, Target, IRB, Serum, Gastroenterology, MASH, Patient, Liver disease, Research design, Nursing

DURHAM, N.C. , Jan. 4, 2024 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, today announced its innovative Precision Medicine Platform, a robust biorepository of 150,000+ samples collected along the patient journey from over 10,000 enrolled patients with 5+ years of clinical follow-up. Combined with Target RWE's longitudinal clinical registry data, the biorepository can be instrumental in genetic and bio-marker identification for patient populations with rapid disease progression or prediction of treatment response.

Key Points: 
  • In the TARGET-NASH registry alone, 80,000+ biospecimen samples have been collected by Target RWE.
  • Target RWE concentrates on disease areas with high unmet medical needs and emerging therapies.
  • This includes a focus on liver disease, metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NAFLD/NASH), and immune-mediated inflammatory conditions in dermatology and gastroenterology.
  • Visit our website to learn more about Target RWE and our precision medicine solutions.

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

Retrieved on: 
Thursday, January 4, 2024
Database, Conference, Elastography, Risk, Registry, NASH, Biopsy, Fatty liver disease, Research, Disease, Health, Cirrhosis, Abstract, MASH, FAST, Patient, Therapy, Fibrosis, Medical imaging

Jesse Fishman, Senior Director, Health Economics and Outcomes Research at Madrigal, stated, “We are gaining important new insights about the serious risks and complications associated with uncontrolled NASH through analyses of real-world data from patient registries and health system databases.

Key Points: 
  • Jesse Fishman, Senior Director, Health Economics and Outcomes Research at Madrigal, stated, “We are gaining important new insights about the serious risks and complications associated with uncontrolled NASH through analyses of real-world data from patient registries and health system databases.
  • The serious burden of uncontrolled NASH on patients and the health system is coming into focus: as the disease progresses to cirrhosis, patients face markedly elevated risk of liver-related and cardiovascular outcomes.
  • Among patients with cirrhosis, ≥25% were not seen by a specialist at the recommended frequency of once per year.
  • This finding underscores the necessity of revisiting current cardiovascular risk models for patients with NASH to incorporate more holistic and liver-specific variables.

Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH/Liver Fibrosis at NASH-TAG 2024

Retrieved on: 
Thursday, January 4, 2024
Liver, Conference, NASH, Drug development, Antibody, Cirrhosis, Cancer, Phagocytosis, Federal Medical Centres, DSM-IV codes, Poster, Liver failure, Research fellow, Liver cancer, Diagnosis, Therapy, NK, Vaccine

SHANGHAI and WARREN, N.J., Jan. 3, 2024 /PRNewswire/ -- Laekna (2105.HK), a clinical-stage biotechnology company, today announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah. The presentation will showcase a novel antibody-based aHSC depletion discovery platform and introduce preclinical anti-fibrosis data of a bi-functional NK-aHSC engager candidates derived from this platform.

Key Points: 
  • Laekna has developed a proprietary antibody-based drug discovery platform of activated hepatic stellate cells (aHSC) depletion for liver fibrosis.
  • This platform enables Laekna to continually discover and develop the next generation therapeutics against liver fibrosis and potentially other types of fibrotic diseases.
  • "Liver fibrosis, metabolic diseases, and cancer are the three major indications that Laekna aims to tackle.
  • In vivo, antibodies with enhanced effector function showed significant anti-fibrotic effects in two different liver fibrosis animal models.

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 3, 2024
Fatty liver disease, Conference, Therapy, NASH

CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 pm PT.

Key Points: 
  • CONSHOHOCKEN, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 pm PT.
  • The presentation will be webcast and an archived recording will be available for replay in the Investors section of the Madrigal website after the event.

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Retrieved on: 
Wednesday, January 3, 2024
Compensated emancipation, Employment, Fatty liver disease, NASH, Obesity

The equity award was approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee’s acceptance of employment with Terns.

Key Points: 
  • The equity award was approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and was made as a material inducement to the employee’s acceptance of employment with Terns.
  • The Company granted the employee options to purchase 19,000 shares of Terns common stock to the new employee.
  • The options have a 10-year term and an exercise price per share equal to $6.49, which was the closing price of Terns’ common stock on December 29, 2023, the last trading day prior to the date of grant.
  • The options vest over four years, subject to the employee’s continued service through the applicable vesting dates.

Poxel Announces its Financial Calendar for 2024

Retrieved on: 
Wednesday, January 3, 2024
Fatty liver disease, DSM-IV codes, Calendar, NASH

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its calendar for the publication of financial information for 2024.